Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives $24.15 Consensus Price Target from Analysts

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has been assigned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $24.1538.

A number of research analysts have recently issued reports on the stock. UBS Group set a $18.00 price objective on shares of Compass Pathways in a report on Thursday, May 7th. B. Riley Financial started coverage on shares of Compass Pathways in a report on Friday, April 24th. They issued a “buy” rating and a $17.00 target price on the stock. Maxim Group raised their price target on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Wall Street Zen upgraded Compass Pathways from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Compass Pathways in a report on Tuesday, July 7th.

Compass Pathways Stock Performance

NASDAQ CMPS opened at $11.26 on Friday. The company has a fifty day simple moving average of $12.51 and a 200 day simple moving average of $9.01. Compass Pathways has a 12-month low of $3.92 and a 12-month high of $15.40. The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.52 billion, a P/E ratio of -3.57 and a beta of 2.47.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Sell-side analysts predict that Compass Pathways will post -1.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CMPS. Toronto Dominion Bank grew its stake in Compass Pathways by 152.9% in the 4th quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after purchasing an additional 1,529,013 shares during the period. Nantahala Capital Management LLC raised its stake in shares of Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after purchasing an additional 1,350,698 shares during the period. Ameriprise Financial Inc. bought a new stake in shares of Compass Pathways during the 3rd quarter worth $6,926,000. Orbimed Advisors LLC purchased a new position in shares of Compass Pathways in the 1st quarter worth about $6,363,000. Finally, Siren L.L.C. purchased a new position in shares of Compass Pathways in the 4th quarter worth about $6,900,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.